Oxford Biotherapeutics Ltd.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
2
Ending by 2030
Feb 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 13, 2026The maintenance fee for Crtam Antibodies and Methods of Treating Cancer (US 11,673,963) comes due Dec 13, 2026. Unpaid by Jun 14, 2027, it lapses early.
- 1 fee due May 10, 2027The maintenance fee for Antibodies Specific to Cadherin-17 (US 9,181,339) comes due May 10, 2027. Unpaid by Nov 10, 2027, it lapses early.
- 1 fee due Jun 1, 2027The maintenance fee for Protein (US 9,200,055) comes due Jun 1, 2027. Unpaid by Dec 1, 2027, it lapses early.
- 1 fee due Jul 5, 2027The maintenance fee for ANTI-ROR1 Antibodies and Methods of Use for Treatment of Cancer (US 9,228,023) comes due Jul 5, 2027. Unpaid by Jan 5, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 23, 2026
- Nov 17 US 12,799,221 Crtam Antibodies and Methods of Treating Cancer
- Nov 17 US 12,799,199 Antibodies and Methods of Use
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 8 of 8
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,084,034 | Proteins In force · High confidence | In force | High confidence | |
| US 9,200,055 | Protein In force · High confidence | In force | High confidence | |
| US 9,181,339 | Antibodies Specific to Cadherin-17 In force · High confidence | In force | High confidence | |
| US 9,228,023 | ANTI-ROR1 Antibodies and Methods of Use for Treatment of Cancer In force · High confidence | In force | High confidence | |
| US 10,081,682 | Conjugated Antibodies Against LY75 for the Treatment of Cancer In force · High confidence | In force | High confidence | |
| US 12,799,221 | Crtam Antibodies and Methods of Treating Cancer In force · Medium confidence | In force | Medium confidence | |
| US 11,673,963 | Crtam Antibodies and Methods of Treating Cancer In force · High confidence | In force | High confidence | |
| US 12,799,199 | Antibodies and Methods of Use In force · High confidence | In force | High confidence |
Also on record, not counted in the 8: 1 patent in force now held by others · 11 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 10 abandoned · 9 no status recorded